ZIOPHARM Oncology Inc.(NASDAQ:ZIOP) presently has five clinical-stage product candidates


Boston, MA, 07/01/2013 (financialstrend) – SAC Capital Advisors assembled the most valuable position by investing more than 1.4 million in ZIOPHARM Oncology Inc.(NASDAQ:ZIOP). Hayman Advisors also initiated $0.6 million during the quarter. The other funds with the company include RA Capital management, Millenium management and First Eagle Investment management.

Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) which opened at $2.28 had declined by 8.26 percent to end up the day at $2.11 on Friday. The decline in the shares of the company is about $0.19 per share for the day. The price range of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) varied from as low as $2.08 to a peak value of $2.29. The 52 week low of the company is at $1.49 and the high value was $6.33.

 The total outstanding shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) is 83.56 million shares which accounts for a huge market capitalization of 176.32 million for ZIOPHARM Oncology Inc. (NASDAQ:ZIOP). Trading volume of the shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) for last Friday was 1.74 million shares which was low when compared to the average trading volume of 1.86 million shares. The institutional investors of the company contribute for around 52 percent of the total outstanding shares.

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) is a biopharmaceutical company that discovers and develops new cancer therapies. The company does lot of research to develop therapeutics for patients. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has presently got five clinical-stage product candidates and multiple research stage candidates. The company’s clinical program include palifosfamide (ZIO-201), IL-12 DNA, indibulin (ZIO-301) and darinaparsin (ZIO-101). Palifosfamide (ZIO-201) is a deoxyribonucleic acid (DNA)-targeted cancer treatment mediated by aldehyde dehydrogenase (ALDH), an enzyme associated with cancer stem cells, which has a favorable toxicity profile. IL-12 DNA is a DNA therapeutic which is delivered to the patient’s tumor and expresses interleukin-12, which is a protein that controls anti-cancer immune responses.